Trial Profile
A Phase IIb, Multi-center, Randomized, Double-blind, Placebo-controlled, Multi-dose, Four-period, Cross-over Study of Two Doses of Formoterol Fumarate MDI (PT005; 7.2 and 9.6 microg Ex-actuator), Administered Twice Daily for 1 Week in Patients With Moderate to Very Severe COPD, Compared to Open Label Marketed Formoterol Fumarate Inhalation Powder (Foradil Aerolizer, 12 microg) as an Active Control.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2014
Price :
$35
*
At a glance
- Drugs Formoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 17 Sep 2010 Actual initiation date (Jul 2010) added as reported by ClinicalTrials.gov.
- 17 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 15 Jan 2010 New trial record